Revolution Medicines Appoints Frank Clyburn to Expanded Board
PremiumCompany AnnouncementsRevolution Medicines Appoints Frank Clyburn to Expanded Board
2M ago
Revolution Medicines reiterates 2024 GAAP net loss guidance
Premium
The Fly
Revolution Medicines reiterates 2024 GAAP net loss guidance
2M ago
Revolution Medicines reports Q2 EPS (81c), consensus (77c)
Premium
The Fly
Revolution Medicines reports Q2 EPS (81c), consensus (77c)
2M ago
Revolution Medicines price target raised to $56 from $44 at H.C. Wainwright
PremiumThe FlyRevolution Medicines price target raised to $56 from $44 at H.C. Wainwright
3M ago
Revolution Medicines price target raised to $57 from $43 at Piper Sandler
Premium
The Fly
Revolution Medicines price target raised to $57 from $43 at Piper Sandler
3M ago
Revolution Medicines price target raised to $53 from $48 at Leerink
Premium
The Fly
Revolution Medicines price target raised to $53 from $48 at Leerink
3M ago
Revolution Medicines Balances 2024 Loss Projection with Promising Cancer Drug Trials
PremiumCompany AnnouncementsRevolution Medicines Balances 2024 Loss Projection with Promising Cancer Drug Trials
3M ago
Tesla downgraded, Booking Holdings upgraded: Wall Street’s top analyst calls
Premium
The Fly
Tesla downgraded, Booking Holdings upgraded: Wall Street’s top analyst calls
3M ago
Revolution Medicines initiated with an Overweight at Barclays
Premium
The Fly
Revolution Medicines initiated with an Overweight at Barclays
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100